Nasser Khaled Altorki, M.B., B.Ch.

Thoracic Surgery
Nasser Altorki

"What we hope to do is assemble a world class medical and research team that can provide our patients with first rate medical care and bring them the most advanced treatments."

Dr. Nasser Altorki is a Professor of Cardiothoracic Surgery and the Director of the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center. Following medical school in Cairo, Egypt, Dr. Altorki completed his residency in general surgery at the University of Chicago Hospital, where he subsequently completed a fellowship in Thoracic and Cardiovascular Surgery. Upon completion of his fellowship, Dr. Altorki began his hospital and teaching appointments at the Weill Cornell Medical College of Cornell University.

Dr. Altorki is a renowned thoracic surgeon to students and colleagues who are particularly interested in esophageal and lung cancer surgery and research. His professional interests include: lung cancer immunotherapy and prevention; esophageal diseases, such as gastroesophageal reflux and the etiology of esophageal motor disorders; the biology, staging and therapy for esophageal carcinoma; new clinical trials in cancer; mediastinal tumors; thymomas and clincial trials in lung and esophageal cancer. His surgical interests focus on minimally invasive surgery for lung and esophageal diseases.

Dr. Altorki is a member of several medical societies that focus on thoracic and cardiac surgery, as well as cancer and gastro-esophageal research and disease prevention. He has published a number of journal articles, book chapters and manuscript reviews on these topics.


    Rated One of New York Magazine's Best Doctors.

  One of America's Top Doctors.



Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Empire Blue Cross/Blue Shield [HMO]
  • Fidelis Care
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • United Health Care



1. Moossa AR, Altorki NK: Pancreatic biopsy. Surg Clin North Am 1983;63:1205-14.

2. Hamerjos A, Altorki NK, Garberoglio C, Moossa AR: Effect of prostaglandin E2 on endocrine and exocrine pancreatic function. Surg Gastroenterol 1983;2:189.

3. Skinner DB, Altorki NK, Ferguson M, Little AG: Zenker's diverticulum: Clinical features and surgical management. Diseases of the Esophagus 1988;1:19.

4. Altorki NK, Skinner DB: Pathophysiology of gastroesophageal reflux. Am J Med 1989 June; ;86:685-89.

5. Altorki NK, Skinner DB, Segalin A, Ferguson MK, Little AG: Indications for esophagectomy in nonmalignant Barrett's esophagus: A 10 year experience. Ann Thorac Surg 1990 May; 49: 724-7.

6. Altorki NK, Skinner DB: En bloc esophagectomy: The first 100 patients. Hepatogastroenterology 1990; 37:360-3.

7. Altorki NK, Skinner DB: Adenocarcinoma in Barrett's esophagus. Seminars in Surgical Oncology 1990 Aug ; 6:274-8.

8. Nanus D, Kelsen D, Mentle I, Altorki NK, Albino A: Infrequent point mutations of ras oncogenes in gastric cancers. Gastroenterology 1990;98:955-60.

9. Libby D, Altorki NK, Gold J, Pitts WR Jr., Bander N: Simultaneous pulmonary and renal malignancy. Chest 1990;98:153-6.

10. Rodriquez E, Rao PH, Altorki NK, Albino A, Ladanyi M, Kelsen D, Jhanwar S, Changanti RS: 11p13-15 is a specific region of chromosomal rearrangement in gastric and esophageal adenocarcinoma. Cancer Research 1990;50:6410-6416.

11. Altorki NK, Skinner DB, Ferguson MK, Little AG: Barrett's adenocarcinoma: Long term survival and recurrence patterns. In: Ferguson MK, Little AG, Skinner DB (eds) Diseases of the Esophagus. Volume I: Malignant Diseases. Mt. Kisco, New York, 1990:229-238.

12. Altorki NK, Sunagawa M, Little A, Skinner DB: High-grade dysplasia in the columnar-lined esophagus. Am J Surg 1991 Jan;161:97-100.

13. Altorki NK, Sunagawa M, Migliore M, Skinner DB: Benign esophageal tumors. Dis of the Esophagus 1991;4:15-19.

14. Altorki NK, Lambroza A: Treatment of achalasia. Gastrointest Endosc 1991, Nov-Dec;37(6):652-3.

15. Libby DM, Klein L, Altorki NK: Aspiration of the nasal septum: a new complication of cocaine abuse. Ann of Intern Med 1992;116:567-68.

16. Perone RW, Henschke CI, Davis SD, Romano P, Altorki NK: High-resolution CT for diagnosis and treatment of pulmonary aspergillosis. Complications in Surg 1992;11:4:24-33.

17. Altorki NK: Radical esophagectomy. Semin Thorac Cardiovasc Surg 1992;4:4:324-7.

18. Aikou T, Altorki NK, Skinner DB, Baba M, Shimazu H: Lymph node dissection for carcinoma of the cardia: Is it worthwhile? Recent Advances in Diseases of the Esophagus, Nabeya K, Hanaoka T, Nogami H (eds) Selected papers in 5th World Congress of the International Society for Diseases of the Esophagus, Kyoto, Japan, 1992:657-62.

19. Baba M, Altorki NK, Skinner DB, Aikou T, Shimazu H: Lymph node metastasis of squamous cell carcinoma in the thoracic esophagus as a prognostic factor. Recent Advances in Disease of the Esophagus, Nabeya K, Hanaoka T, Nogami H (eds). Selected papers in 5th World Congress of the International Society for Diseases of the Esophagus, Kyoto, Japan, 1992:702-713.

20. Altorki NK, Sunagawa M, Skinner DB: Thoracic esophageal diverticula: Why is operation necessary? J Thorac Cardiovasc Surg 1993;105:260-264.

21. Altorki NK: Squamous cell cancer of the esophagus. Postgrad Gen Surg 1993;Feb:290-291.

22. Altorki NK: Malignant esophagorespiratory fistula: A commentary. Postgrad Gen Surg 1993;Feb:292-294.

23. Donovan WD, Yankelevitz DF, Henschke CI, Altorki NK, Nash T: Endobronchial spread of bronchoalveolar carcinoma. Chest 1993;104:951-3.

24. Altorki NK, Schwartz GK, Blundell M, Davis BM, Kelsen DP, Albino AP: Characterization of cell lines established from human gastric-esophageal adenocarcinomas: Biological phenotype and invasion potential. Cancer 1993;72:3:649-57.

25. Rosengart TK, Kreiger K, Lang S. Gold JP, Altorki NK, Roussel M, Debois WJ, Isom OW: Reoperative coronary artery bypass surgery: Improved preservation of myocardial function with retrograde cardioplegia.Circulation1993;88(2):330-5.

26. Burdett PH, Henschke CI, Libby DM, Altorki NK, Skinner DB: Bronchogenic spread of TB in a patient with adenocystic carcinoma of the right upper lobe bronchus. Infect Med 1993;10(11):55-58.

27. Schwartz GK, Wang H, Lampen N, Altorki NK, Kelsen D, Albino AP: Defining the invasive phenotype of proximal gastric cancer cells. Cancer 1993;73(1):22-27.

28. Altorki NK, Migliore M, Skinner DB: Esophageal carcinoma with airway invasion: Evolution and choices of therapy. Chest 1994, Sept;106:742-45.

29. Albino AP, Jaehne J, Altorki NK, Blundell M, Urmacher C, Lauwers G, Niedzwiecki D, Kelsen DP: Amplification of HER-2/neu gene in human gastric adenocarcinomas: Correlation with primary site. Eur J Surg Oncol 1995;21:56-68.

30. Altorki NK: Extended resections in the management of esophageal carcinoma. Curr Opin Gen Surgy 1994:113-116.

31. Magovern CJ, Altorki NK: Achalasia of the esophagus. Chest Surg Clin of N Am. 1994 Nov;4:721-39.

32. Altorki NK, CALGB Thoracic Surgery Group: Results of Cancer and Leukemia Group B protocol 8935: A multiinstitutional phase II trimodality trial for Stage IIIA (N2) nonsmall cell lung cancer. J Thorac and Cardiovasc Surg 1995;109:473-85.

33. Wand A, Davis SD, Yankelevitz DF, Altorki NK, Henschke CI. Esophageal perforation due to Sengstaken-Blakemore tube. Complications in Surg 1995:Feb 79-86.

34. Nabeya Y, Loganzo F, Maslak P, Lai L, de Oliveira AR, Blundell ML, Schwartz GK, Altorki NK, Kelsen DP, Albino AP: The mutational status of p53 protein in gastric/esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. Int J Cancer 1995 Feb 20;64:37-46.

35. Dang M, Wand A, Yankelevitz DF, Altorki NK, Henschke CI. Diagnosis of pulmonary embolism using spiral CT. Complications of Surg 1995;14:365-367.

36. Altorki NK, Snady H, Skinner DB: Endosonography for cancer of the esophagus and cardia: Is it worthwhile? Dis of the Esophagus 1996;9:198-201.

37. Almeida JCM, Rajasekaran A, Godwin T, Quaroni A, Rodriquez-Boulan E, Altorki NK: Barrett's esophagus and adenocarcinoma of the esophagus and cardia ubiquitously express sucrase-isomaltase and crypt cell antigen. Dis of the Esophagus 1996;9:191-197.

38. Velasco FT, Ko W, Rosengart T, Altorki NK, Lang S, Gold JP, Krieger KH, Isom OW: Cost containment in cardiac surgery: Results with a critical pathway for coronary bypass at The New York Hospital-Cornell University Medical Center. Best Pract Benchmarking Healthc 1996 Jan-Feb;1:21-28.

39. Helm RE, Klemperer JD, Rosengart TK, Gold JP Peterson P, Debois W, Altorki NK, Lang S, Thomas S, Isom OW, Krieger KH. Intraoperative autologous blood donation preserves red cell mass but does not decrease postoperative bleeding. Ann Thorac Surg 1996 November;62:1431-41. Review.

40. Almeida JCM, Rajasekaran AK, Rodriguez-Boulan E, Altorki NK: Barrett's esophagus and adenocarcinoma changes in E-cadherin and a6/b4 integrin expression. In: Peracchia A, Rosati R, Bonavina L, Fumagalli U, Bona S, Chella B (eds) Dis of the Esophagus 1996:817-23.

41. Magovern CJ, Mack CA, Gu M, Hoda S, Altorki NK. Primary inflammatory fibrosarcoma of the esophagus. Ann Thorac Surg 1996 Dec;62;1848-50.

42. Altorki NK, Girardi L, Skinner D: Extended resections for carcinoma of the thoracic esophagus and cardia. In: Peracchia A, Rosati R, Bonavina L, Fumagalli U, Bona S, Chella B (eds) Diseases of the Esophagus 1996:273-9.

43. Yankelevitz DF, Henschke CI, Koizumi J, Altorki NK, Libby D: CT-guided transthoracic needle biopsy of small solitary pulmonary nodules. Clin Imaging 1997 Mar-Apr;21:107-110.

44. Altorki NK, Skinner DB. Occult cervical nodal metastasis in esophageal cancer. Preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg 1997 Mar;113;540-4.

45. Altorki NK, Oliviera S, Schrump D: The epidemiology and molecular biology of Barrett's adenocarcinoma. Sem Surg Oncol 1997 July-August; 13(4):270-80.

46. Korst RJ, Altorki NK. Extent of resection and lymphadenectomy in early Barrett's cancer. Dis Esophagus 1997 July;10:172-8.

47. Altorki NK, Loinaz C: Pitfalls and complications of colon interposition. Chest Surg Clinics of NA 1997 Aug; 7:533-49.

48. Soslow R, Liang Y, Altorki NK: Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. J Thorac Cardiovasc Surg 1997 Nov; 114:838-43.

49. Mendes de Almeida JC, Chaves P, Periera D, Altorki NK. Is Barrett's esophagus the precursor of most adenocarcinomas of the esophagus and cardia? A biochemical study. Ann Surg 1997 Dec; 226:725-35.

50. Altorki NK, Girardi L, Skinner DB: En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 1997 Dec; 114:948-56.

51. Yankelevitz DF, Henschke CI, Koizumi J, Altorki NK, Libby D. CT guided transthoracic needle biopsy following negative fiberoptic bronchoscopy in solitary pulmonary nodules. Clinl Imaging 1998 Jan-Feb; 21:107-110.

52. Altorki NK, Yankelevitz D, Skinner DB: Massive hiatal hernias: The anatomical basis of repair. J Thorac Cardiovasc Surg 1998 Apr ;115:828-35.

  1. Zhang F, Subbaramaiah K, Altorki NK, Dannenberg AJ: Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998 Jan 23; 273:2424-8.
  1. Helm RE, Rosengart TK, Klemperer JD, Gomez M, DeBois WJ, Gold JP, Ko W, Velasco F, Altorki NK, Lang SA, Thomas S, Isom OW, Krieger KH: Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998 Jan; 65(1):125-36.
  1. Klemperer JD, Ko W, Krieger KH, Connolly M, Rosengart TK, Altorki NK, Lang SJ, Isom OW: Cardiac operations in patients with cirrhosis. Ann Thorac Surg 1998 Jan; 65(1):85-7.
  1. Rosengart TK, DeBois W, O'Hara M, Helm R, Gomez M, Lang SJ, Altorki NK, Ko W, Hartman GS, Isom OW, Krieger KH: Retrograde autologous priming (RAP) for cardiopulmonary bypass: A safe and effective means of decreasing hemodilution and transfusion requirements. J Thorac Cardiovasc Surg 1998 Feb; 115(2):426-39.
  1. Gure AO, Altorki NK, Stockert E, Scanlan MJ, Old LJ, Chen YT: Human lung cancer antigens recognized by autologous antibodies: Definition of a novel cDNA derived from the tumor suppressor gene (TSG) locus on chromosome 3p21.3. Cancer Res 1998 Mar;58:1034-41.
  1. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK: Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 1998 November;4:2885-2890.
  1. Rosengart T, O'Hara M, Lang S, Ko W, Altorki NK, Krieger K, Isom OW: Outcome analysis of 245 Carbo Medics and St. Jude valves implanted at the same institution. Ann Thorac Surg 1998 Nov; 66:1684-1691.
  1. Soslow RA, Baergen RN, Remotti H, Altorki NK: Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus. Mod Pathol 1999 Mar; 12(3):239-250.
  1. Altorki NK: The rationale for radical resection. Surg Oncol Clin 1999 Apr; 8(2):295-305. Review.
  1. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ: Curcumin inhibits cyclooxygenase-2 transcription in bile acid and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 1999 Mar; 20(3):445-51.
  1. Subbaramaiah K; Altorki, NK; Chung WJ; Mestre JR; Sampat A; Dannenberg AJ: Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999 April;16;274(16):10911-10915.
  1. Soslow RA; Altorki NK; Yuang G; Xie D; Yang CS: mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 1999 June;12(6):580-86.
  1. Soslow RA, Nabeya Y, Ying L, Blundell M, Altorki NK: Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma. Histopathology 1999 Jul; 35:31-7.
  1. Henschke CI; McCauley DI; Yankelevitz DF; Naidich DP; McGuinness G; Miettinen OS; Libby DM; Pasmantier MW; Koizumi J; Altorki NK; Smith JP: Early Lung Cancer Action Project: overall design and finding from baseline screening. Lancet 1999 July;354(9173):99-105.
  1. Scanlan MJ; Altorki NK; Gure AO; Williamson B; Jungbluth A; Chen YT; Old LJ: Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Letters 2000, Mar; 150 (2):155-164.
  1. Jungbluth AA, Stockert E, Chen Y-T, Kolb D, Iversen K, Coplan K, Williamson B, Altorki NK, Busam KF and Old LJ. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J of Cancer 2000 August;83(4):493-497.
  1. Ferguson MK; Landreneau RJ; Hazelrigg SR; Altorki NK; Naunheim KS; Zwischenberger JB; Kent M; Yim APC: Long-term outcome after resection for bronchial carcinoid tumors. Eur J Cardiothorac Surg 2000 August;18(2):156-61.
  1. Altorki, NK: Three-field lymphadenectomy for esophageal cancer. Chest Surg Clin N Am 2000 August;10(3):553-560.
  1. Park BJ, Louie O, Altorki NK: Staging and the Surgical Management of Lung Cancer. Radiol Clin N Am 2000 May;38(3): 545-61, ix.
  1. Gure A.O.; Stockert E; Scanlan MJ; Keresztes RS; Jager D; Altorki NK, Old LJ; Chen YT: Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proceedings Natl Acad Scie, USA 2000 April;11;97(8):4198-4203.
  1. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki NK, Old LJ: Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001 June;15;92(6):856-60.
  1. Altorki NK, Kent M, Pasmantier M. Detection of early stage lung cancer: Computed tomographic scan or chest radiograph? J Thorac Cardiovasc Surg 2001 June;121(6):1053-7.
  1. Henschke CI, Naidich DP, Yankelevitz DF, McCauley DI, McGuiness G, Smith JP, Libby D, Pasmantier M, Koizumi J, Vazquez M, Flieder D, Altorki NK, Miettinen OS. Early lung cancer action project: initial findings of repeat screening. Cancer 2001 Jul 1;92(1):153-9.
  1. Yoshimatsu K, Altorki NK, Zhang F, Jakobsson P, Dannenberg AJ, Subbaramaiah K: Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001 Sept; 7(9):2669-74.
  1. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby D, Pasmantier M, Koizumi, Altorki NK, Smith JP. Early lung cancer action project: a summary of the findings on baseline screening. Oncologist 2001;6(2) 147-52. Review.
  1. Altorki NK, Skinner D. Should en-bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg 2001 Nov; 234 (5)581-87.
  1. Soslow RA, Petersen CG, Remotti H, Altorki NK. Acidic fibroblast growth factor (FGF-1) is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma. Dis Esophagus 2001;14(1):23-7.
  1. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001 Sept; 2:544-51. Review.
  1. Zhang F, Altorki NK, Wu YC, Soslow RA, Subbaramaiah K, Dannenberg AJ. Duodenal reflux induces Cyclooxygenase-2 in the esophageal mucosa of rats. Evidence for involvement of bile acids. Gastroenterology 2001 Dec;121(6):1391-9.
  1. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K. Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci 2001 Dec;952:109-115.
  1. Henschke CI, Yankelevitz DF, Libby DM, McCauley D, Pasmantier M, Altorki NK, Smith JP, Miettinen OS. Early lung cancer action project: annual screening using single-slice helical CT. Ann NY Acad Sci 2001 Dec;952:124-34.
  1. Lee LY, DeBois W, Krieger KH, Girardi LN, Russo L, McVey J, Ko W, Altorki NK, et al. The effects of platelet inhibitors on blood use in cardiac surgery. Perfusion 2002 Jan; 17(1): 33-37.
  1. Jungbluth AA, Chen Y-T, Stockert E., Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki NK, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001; 92(6) 856--860. Int J Cancer 2002 Feb 20;97(6):878.
  1. Park BJ, Altorki NK. Diagnosis and Management of Early Lung Cancer. Surg Clin North Am. 2002 Jun;82(3):457-76, v. Review.
  1. Kent MS, Flieder DF, Port JP, Altorki NK. Proliferative myositis: A rare pseudosarcoma of the chest wall. Ann Thorac Surg 2002 Apr;73(4):1296-1298.
  1. Altorki NK, Kent M, Ferrara CA, Port JL. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann of Surg 2002 Aug;236(2):177-183.
  1. Gnajatic S, Jager E, Altorki NK, Matsuo M, Lee S-Y, Chen W, Chen Q, Nagata Y, Atanackovic D, Chen Y-T, Ritter G, Cebon J, Knuth A, Old L. CD8+ T cell responses against a dominant cryptic HLA-A2 epitope following NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11813-8.
  1. Girardi LN, Krieger KH, Altorki NK, Mack CA, Lee LY, Isom OW. Ruptured descending and thoracoabdominal aortic aneurysms. Ann Thor Surg 2002 Oct;74(4):1066-70.
  1. Port JL, Kent M, Altorki NK. Early lung cancer detection and treatment strategies. Surg Oncol 2002 Dec;11(4):191-9.
  1. Stellman SD, Chen Y, Muscat JE, Djordjevic MV, Richie JP Jr, Lazarus P, Thompson S, Altorki NK, Berwick M, Citron ML, Harlap S, Kaur TB, Neugut AI, Olson S, Travaline JM, Witorsch P, Zhang ZF. Lung cancer risk in white and black Americans. Ann Epidemiol. 2003 Apr;13(4):294-302.
  1. Port JP, Kent M, Korst RJ, Bacchetta M, Altorki NK. Thoracic Esophageal Perforations: A Decade of Experience. Ann Thorac Surg 2003 Apr;75(4):1071-4.
  1. Muscat JE, Chen SQ, Richie Jr. JP, Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD. Risk of lung carcinoma among users of nonsteroidal anti-inflammatory drugs. Cancer 2003 Apr 1;97(7):1732-6.
  1. Bacchetta MD, Korst RJ, Altorki NK, Port JL, Isom OW, Mack CA. Resection of a symptomatic pericardial cyst using the computer-enhanced da Vinci Surgical System. Ann Thorac Surg. 2003 Jun;75 (6):1953-5.
  1. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ. Celecoxib, a selective COX-2 inhibitor, enhances the response to preoperative Paclitaxel and Carboplatin in early stage lung cancer. J Clin Oncol 2003 Jul;21 (14):2645-2650.
  1. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, DuPont B, Ritter G, Chen YT, Knuth A, Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7.
  1. Altorki NK, Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of cancers of the upper digestive tract. Prog Exp Tumor Res. 2003;37:107-23.
  1. Korst RJ, Altorki NK. High grade dysplasia: surveillance, mucosal ablation, or resection? World J Surg. 2003 Sep;27(9):1030-4.
  1. Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK. Tumor Size Predicts Survival Within Stage IA Non-Small Cell Lung Cancer. Chest. 2003 Nov;124(5):1828-33.
  1. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg. 2003 Nov; 126(5): 1603-8.
  1. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg, 2004 Jan; 77(1): 254-9.
  1. Almahmeed T, Boyle JO, Cohen EG, Carew JF, Du B, Altorki NK, Kopelovich L, Fang JL, Lazarus P, Subbaramaiah K, Dannenberg AJ. Benzo[a] pyrene phenols are more potent inducers of CYPlAl, CYP1B1 and COX-2 than benzo[a] pyrene glucuronides in cell lines derived from the human aerodigestive tract. Carcinogenesis, 2004 May; 25 (5):793-9.
  1. Altorki NK. COX-2: a target for prevention and treatment of esophageal cancer. J Surg Res. 2004 Mar;117(1):114-20.
  1. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, DuPont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol. 2004 Mar; 1;172(5):3289-96.
  1. Libby DM, Smith JP, Altorki NK, Pasmantier MW, Yankelevitz D, Henschke CI. Managing the small pulmonary nodule discovered by CT. Chest 2004 Apr; 125 (4): 1522-9.
  1. Altorki NK, Subbaramaiah K. Dannenberg AJ. COX-2 inhibition in upper aerodigestive tract tumors. Semin Oncol. 2004 Apr:31 (2 suppl 7);30-6. Review
  1. Port JL, Yamaguchi K., Du B, De Lorenzo M, Chang M, Heerdt PM, Kopelovich L, Marcus CB, Altorki NK., Subbaramaiah K, Dannenberg AJ. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004 Aug 5.
  1. Pass HI, Altorki, NK. Computerized tomographic nodule heterogeneity: present and future impact on indications for sublobar resections. Clin Lung Cancer. 2004 Jul:6(1):20-7.
  1. Kent MS, Korst RJ, Gayle LB, Port JL, Altorki NK. A simple solution for management of the postpneumonectomy empyema cavity. Ann Thorac Surg. 2004 Sep: 78(3):1107-8.
  1. Port JL, Kent M, Korst RJ, Lee PC, Levin MA, Flieder D, Altorki NK Surgical resection for lung cancer in the octogenarian. Chest.2004 Sep; 126(3):733-8.
  1. Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. Thorac Surg Clin. 2004 Feb: 14(1):1-13.
  1. Korst RJ, Altorki NK. Imaging for esophageal tumors. Thorac Surg Clin 2004 Feb; 14 (1):61-9.
  1. Moraitis D, Du B, DeLorenzo MS, Boyle J, Weksler B, Cohen E, Carew J, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg A. Levels of Cyclooxygenase-2 Are Increased in the Oral Mucosa of Smokers: Evidence for the Role of Epidermal Growth Factor Reciptor and its Ligands. Cancer Res 2005 Jan 15:65: (2).
  1. Altorki NK. Invited Commentary. Ann Thorac Surg.2005 Mar;79(3):979.
  1. Korst RJ, Gold HT, Kent MS, Port JL, Lee PC, Altorki NK. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg. 2005 Mar;129(3):652-60.
  1. Korst RJ, Altorki NK. Imaging for esophageal tumors. Radiol Clin North Am. 2005 May;43(3):611-9.
  1. Port JL, Korst RJ, Lee PC, Levin MA, Becker DE, Keresztes, R, Altorki NK. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg. 2005 May;79(5):1686-90.
  1. Altorki NK. En-bloc esophagectomy--the three-field dissection. Surg Clin North Am. 2005 Jun;85(3):611-9, xi. Review
  1. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, Subbaramaiah K, Dannenberg AJ. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res. 2005 June1;11(11):4191-7
  1. Henschke CI, Shaham D, Yankelevitz DF, Altorki NK. CT screening for lung cancer: past and ongoing studies. Semin Thorac Cardiovasc Surg. 2005 Summer
  1. Altorki NK, Yankelevitz DF, Vazquez MF, Kramer A, Henschke CI. Bronchioloalveolar carcinoma in small pulmonary nodules: clinical relevance. Semin Thorac Cardiovasc Surg. 2005 Summer;17(2):123-7.
  1. Du B, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Tobacco smoke stimulates the transcription of amphiregulin in human oral epithelial cells: evidence of a cyclic AMP-responsive element binding protein-dependent mechanism. Cancer Res. 2005 Jul 1:65(13):5982-8.
  1. Flieder DB, Port JL, Korst RJ, Christos PJ, Levin MA, Becker DE, Altorki NK. Tumor size is a determinant of stage distribution in t1 non-small cell lung cancer.

Chest 2005 Oct; 128(4):2304-8.

  1. Korst RJ, Port JL, Lee PC, Altorki NK. Intrathoracic manifestations of cervical anastomotic leaks after transthoracic esophagectomy for carcinoma. Ann Thorac Surg. 2005 Oct;80(4):1185-90.
  1. Kent MS, Korn P, Port JL, Lee PC, Altorki NK, Korst RJ. Cost effectiveness of chest computed tomography after lung cancer resection: a decision analysis model Ann Thorac Surg. 2005 Oct:80(4):1215-22;discussion 1223-3.
  1. Altorki NK. Bronchioloalveolar carcinoma and ground glass opacities. Ann Thorac Surg. 2005 Oct;80(4):1560-1.
  1. Henschke CI, Altorki NK; I-ELCAP Investigators. CT screening for lung cancer: update 2005. Surg Oncol Clin N Am 2005; 14: 761-776
  1. Altorki NK, I-ELCAP Investigators. An Update of CT Screening for Lung Cancer. Semin Ultrasound CT MR. 2005 Oct; 26(5):348-356
  1. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki, NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005 Nov 15;11(22):8055-62.
  1. Kent MS, Gayle L, Hoffman L, Altorki NK A new technique of subcutaneous colon interposition. Ann Thorac.Surg. 2005 Dec;80(6):2384-6.
  1. Port JL, Andrade RS, Levin MA, Korst RJ, Lee PC, Becker DE, Altorki NK. Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2cm in size or less. J Thorac Cardiovasc Surg.2005 Dec;130(6):1611-5.
  1. Kaplan RN, Riba, RD, Zacharoulis s, Bramley AH, Vincent L, Jin DK, Shido K, Kerns K, Zhu Z, Wu Y, Port JL, Altorki NK, Port E,. VEGFR-1positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005 Dec 8;438(7069):820-7.

134. Henschke CI, Shaham D, Yankelevitz DF, Altorki NK. CT Screening for Lung Cancer: Past and Ongoing Studies. Seminars in Thoracic and Cardiovascular Surgery, Vol.17,(2): 2005:99-106

  1. Henschke CI, Yankelevitz DF, Miettinen OS, Altorki NK, International Early Lung Cancer Action Program Investigators; Computed Tomographic Screening Lung Cancer: The relationship of disease stage to tumor size. Archives of Internal Medicine 2006; 166: 321-325
  1. Henschke CI, Lee IJ, Wu N, Farooqi A, Khan A, Yankelevitz D, Altorki NK. CT screening for lung cancer: prevalence and incidence of mediastinal masses. Radiology. 2006 May;239(2):586-90.
  1. Henschke CI, Yip R, Miettinen OS, Altorki NK, International Early Lung Cancer Action Program Investigators; Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 2006 Jul; 296; 180-184
  1. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006 Aug;82(2):480-4; discussion 484-5.
  1. Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK. Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg. 2006 Sept;82(3):100915.
  1. Lilenbaum R, Socinski MA, Altorki NK, Hart LL, Keresztes RS, Hariharan S, Morrison ME, Fayyad R, Bonomi P. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4825-32.
  1. Altorki, NK, IELCAP. Survival of Patients with Stage 1 Lung Cancer Detected on CT Screening. New Eng Journal Med 2006 Oct 26: 355(17):1763-1771
  1. HJ Cho, OL Caballero, S Gnjatic, VC Andrade, GW Colleoni, AL Vettore, HH Outtz, S Fortunato, NK Altorki, CA Ferrera, R Chua, AA. Jungbluth, YT Chen, LJ Old, and AJ Simpson. Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 2006 Dec 1: 6:12.
  1. Lee PC, Korst RJ, Port JL, Kerem Y, Kansler AL, Altorki NK. Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size. J Thorac Cardiovasc Surg. 2006 Dec; 132(6):1382-9. Epub 2006 Oct 30.
  1. Port JL, Korst RJ, Lee PC, Kansler AL, Kerem Y, Altorki NK. Surgical resection or multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg. 2007 Feb; 83(2):397-400.
  1. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P. Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 2007;3(2):95-109.
  1. Kim AW, Korst RJ, Port JL, Altorki NK, Lee PC Giant cavernous hemangioma of the distal esophagus treated with esophagectomy. J Thorac Cardiovasc Surg. 2007 Jun;133(6):1665-7
  1. Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007 Jul;84(1):177-81.
  1. Henschke CI, Yankelevitz DF, Altorki NK. The role of CT screening for lung cancer. Thorac Surg Clin. 2007 May;17(2):137-42.
  1. Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, Mazumdar M, Altorki NK. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg. 2007; 84(2):393- 400.
  1. Silva WA Jr., Gnjatic S, Ritter E, Chua r, Cohen T, Hsu M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, Simpson AJ, Caballero OL. PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. Cancer Immun. 2007;7:18.
  1. Huston JM, King H, Maresh A, Liska D, Port JL, Altorki NK, Lee PC. Hernia of Morgagni: case report. J Thorac Cardiovasc Surg 2008; 135(1):212-3.
  1. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Cnjatic S. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A. 2008;105(5):1650-5.
  1. Sica G, Vazquez MF, Altorki N, Port J, Lee PC, Liu Y, Hyjek E, Saqi A. PAX-5 expression in pulmonary neuroendocrine neoplasms: Its usefulness in surgical and fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129(4):556-62.
  1. Altorki NK, Lee PC, Liss Y, Meherally D, Korst RJ, Christos P, Mazumdar M Port JL. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg. 2008; 247(3):434-9.
  1. Wagner PL, Tam W, Lau PY, Port JL, Paul S, Altorki NK, Lee PC. Primary esophageal large T-cell lymphoma mimicking esophageal carcinoma: a case report and literature review. J Thorac Cardiovac Surg. 2008; 135(4):957-8.
  1. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P, Wai J. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clinica Chimica Acts; 2008;393(2):76-84.
  1. John T, Caballero JT, Svobodova SJ, Kong A, Chua R, Browning J, Fortunato S, Deb S, Hsu M, Gedye CA, Davis ID, Altorki N, Simpson AJ, Chen YT, Monk M, Cebon JS. ECSA/DDPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer. Clin Cancer Res. 2008;14(11):3291-8.
  1. Servais E, Paul S, Port JL, Altorki NK, Lee PC. Carcinoid tumor nested within a bronchogenic cyst. J Thorac Cardiovasc Surg. 2008;136(1):227-8.
  1. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008; 248(2):221-6.
  1. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Hölscher A, Lerut T, Law S, Rice TW, Ruol A, vanLanchot JJ, Wong J, DeMeester TR. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248(4):549-56.
  2. Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, Port JL, Yan M, Markowitz SD, Mazumdar M, Tai HH, Subbaramaiah K, Dannenberg AJ. NAD+- dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) 2008 Sep;1(4):241-9.
  1. Abrams JA, Lee PC, Port JL, Altorki NK, Neugut AI. Cigarette smoking and risk of lung metastasis from esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2707-13.

163. Peyre CG, Hagen JA, Demeester SR, Van Lanschot JJ, Hölscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki N, Rice TW, Wong J, Lerut T, DeMeester TR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: A multinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008 Dec;248(6):979-985

  1. Sica G, Wagner PL, Altorki N, Port J, Lee PC, Vazquez MF, Saqi A. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med. 2008 Dec;132(12):1889- 95.

165. Gnjatic S, Wheeler C, Ebner M, Ritter E, Murray A, Altorki N, Ferrara CA, Hepburne-Scott H, Joyce S, Koopman J, McAndrew MB, Workman N, Ritter G, Fallon R, Old LJ. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J Immunol Methods. 2009;341(1-2):50-8.

  1. Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki NK. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009 Jan;137(1):13-9.

167. Paul S, Lee PC, Altorki NK, Stiles BM, Port JL Partial Upper Sternotomy for Anterosuperior Mediastinal Surgery: An Institutional Experience. Ann Surg Oncol. 2009;16(4):1039-42.

  1. Altorki N, Stiles BM. Invited commentary. Ann Thorac Surg. 2009;87(4):1065.
  1. Altorki N. The association between overall survival and the total number of dissected lymph nodes: an artifact caused by the surgical pathologist? Ann Surg. 2009
  1. Gnjatic S, Altorki NK, Tang DN, Tu SM, Kundra V, Ritter G, Old LJ, Logothetis CJ, Sharma P. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res. 2009;15(6):2130-9.
  1. Paul S, Altorki NK, Port JL, Stiles BM, Lee PC. Surgical management of chylothorax. Thorac Cardiovasc Surg. 2009;57(4):226-8.
  1. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009;137(3):615-21.
  1. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Song CJ, Jin BQ, Simpson AJ, Old LJ. Int J Cancer. 2009; 124(12):2893-98.
  1. Paul S, Altorki NK, Stiles BM, Port JL, Lee PC. Images in cardiothoracic surgery. A case of severe heartburn. Ann Thorac Surg. 2009;87(6):1959.
  1. Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N, Mittal V. Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochem Biophys Acta. 2009; 1796(1):33-40. Epub 2009 May 19.
  1. Lee PC, Port JL, Paul S, Stiles BM, Altorki NK. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg. 2009;88(1):186-92; discussion 192-3.
  1. Lee BE, Port JL, Stiles BM, Saunders J, Paul S, Lee PC, Altorki N. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg. 2009;88(4):1100-5.
  1. Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am J Clin Pathol. 2009;132(4):500-5.
  1. Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination. J Immunol. 2009 Oct 1;183(7):4800-8.
  1. Mathé EA, Nguyen GH, Bowman ED, Zhao Y, Budhu A, Schetter AJ, Braun R, Reimers M, Kumamoto K, Hughes D, Altorki NK, Casson AG, Liu CG, Wang XW, Yanaihara N, Hagiwara N, Dannenberg AJ, Miyashita M, Croce CM, Harris CC. MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival. Clin Cancer Res. 2009;15(19); 6192-6200.

181. Gulkarov I, Paul S, Altorki NK, Lee PC. Use of Amplatzer device for endobronchial closure of bronchopleural fistulas. Interact Cardiovasc Thorac Surg. 2009;9(5):901-2. Epub 2009 Aug 6.

  1. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E. Tumor-reactive CD8(+) T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and montanide(R) ISA-51: Association with survival. Int J Cancer. 2010;126(4):909-18.

183. Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, Altorki NK. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg 2010 Feb;139 (2):387-94. Epub 2009; Dec 16

184. Altorki NK. Stereotactic body radiation therapy versus wedge resection for medically inoperable stage I lung cancer: tailored therapy or one size fits all? J Clin Oncol. 2010 Feb 20;28(6):905-7. Epub 2010 Jan 11.

185. Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 2010 Feb 24;102(4):271-4. Epub 2010 Jan 14.

186. Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW, Stiles BM, Port JL, D'Amico TA. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg. 2010 Feb;139(2):366-78.

187. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, Bordogna W, Ottesen LH, Heymach JV. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in earlystage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010 Mar 15;70(6):2171-9. Epub 2010 Mar 9.

188. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010 Jul 1;28(19):3131-7. Epub 2010 Jun 1.

189. Mirza F, Paul S, Stiles BM, Piotti KC, Kawaguchi KR, Altorki NK. Adult onset asthma. Ann Thorac Surg. 2010 Aug;90(2):e31

190. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. Epub 2010 Aug 16.

191. Stiles BM, Mirza F, Port JL, Lee PC, Paul S, Christos P, Altorki NK. Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer. Ann Thorac Surg. 2010 Dec;90(6):1805-11.

192. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, Altorki NK. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: Age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011 Jan;141(1):48-58.

193. Lee PC, Mirza FM, Port JL, Stiles BM, Paul S, Christos P, Altorki NK. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg. 2011May;141(5):1196-206. Epub 2011 Mar 12.

194. Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, Reischl M, Mikut R, Rubin MA, Fend F, Moch H, Soltermann A, Weder W, Altorki NK, Perner S. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma. Lung Cancer. 2011 Oct;74(1):118-23. Epub 2011 Apr 8.

195. Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes R, Beneck D, Paul S, Stiles BM, Zhang Y, Schrump DS. Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial. J Thorac Oncol. 2011 Jun;6(6):1121-7.

196. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA. Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer. Ann Surg Oncol. 2011 Nov;18(12):3362-9. Epub 2011 May 6.

197. Stiles BM, Mirza F, Coppolino A, Port JL, Lee PC, Paul S, Altorki NK. Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease. Ann Thorac Surg. 2011 Aug;92(2):491-6; discussion 496-8. Epub 2011 Jun 24

198. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, Reischl M, Mikut R, Altorki NK, Moch H, Fend F, Staebler A, Bass AJ, Meyerson M, Rubin MA, Soltermann A, Lengerke C, Perner S. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol. 2011 Jul;24(7):944-53. doi: 10.1038/modpathol.2011.49. Epub 2011 Apr 1.

199. Port JL, Mirza FM, Lee PC, Paul S, Stiles BM, Altorki NK. Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery. Ann Thorac Surg. 2011 Dec;92(6):1951-7. Epub 2011 Oct7.

200. Stiles BM, Mirza F, Towe CW, Ho VP, Port JL, Lee PC, Paul S, Yankelevitz D, Altorki NK. Cumulative Radiation Dose From Medical Imaging Procedures in Patients Undergoing Resection for Lung Cancer Ann Thorac Surg. 2011Oct;92(4):1170-9. Epub 2011 July 13.

201. Paul S, Mirza FM, Nasar A, Port JL, Lee PC, Stiles BM, Nguyen AB, Sedrakyan A, Altorki NK. Prevalence, outcomes, and a risk-benefit analysis of diaphragmatic hernia admissions: An examination of the National Inpatient Sample database. J Thorac Cardiovasc Surg. 2011 Oct;142(4):747-54. Epub 2011 Jul 30.

202. Stiles BM, Altorki NK. Screening for lung cancer: challenges for the thoracic surgeon. Surg Oncol Clin N Am. 2011 Oct;20(4):619-35.

203. Field JK, Smith RA, Aberle DR, Oudkerk M, Baldwin DR, Yankelevitz D, Pedersen JH, Swanson SJ, Travis WD, Wisbuba II, Noguchi M, Mulshine JL, Altorki N,; IASLC CT Screening Workshop 2011 Participants. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol. 2012 Jan;7(1):10-9.

204. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner P, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V. Myeloid Progenitor Cells in the Premetastatic Lung Promote Metastases by Inducing Mesenchymal to Epithelial Transition. Cancer Res. 2012 Mar 15;72(6):1384-94. Epub 2012 Jan 26.

205. Paul S, Nasar A, Port JL, Lee PC, Stiles BC, Nguyen AB, Altorki NK, Sedrakyan A. Comparative Analysis of Diaphragmatic Hernia Repair Outcomes Using the Nationwide Inpatient Sample Database. Arch Surg. 2012 Mar 19. [Epub ahead of print].

206. Stiles BM, Nasar A, Mirza FA, Lee PC, Paul S, Port JL, Altorki NK. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg. 2012 Apr 4. [Epub ahead of print]

Honors and Awards

Honor Society, Cairo University 1977


American Cancer Society Award and Fellowship 1983-84